On the other hand, a standard of care chemotherapy for GBM, temozolomide, prevented early tumor growth of U87 CSC-xenograft tumors (data not shown), but comparative analysis of temozolomide and DEspR-inhibition in tumor progression associated with larger tumors, and in temozolomide-resistant U87-CSCs remain to be studied. The gene discussed is FBXW7-AS1; the disease is glioblastoma.